Valeant Company Profile
✉ Email this page to a colleague
What is the competitive landscape for VALEANT
VALEANT has sixty-seven approved drugs.
There are six US patents protecting VALEANT drugs.
There are forty-four patent family members on VALEANT drugs in twelve countries and fifty supplementary protection certificates in fifteen countries.
Summary for Valeant
| International Patents: | 44 |
| US Patents: | 6 |
| Tradenames: | 55 |
| Ingredients: | 45 |
| NDAs: | 67 |
| Patent Litigation for Valeant: | See patent lawsuits for Valeant |
Drugs and US Patents for Valeant
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Valeant Pharm Intl | PERMAX | pergolide mesylate | TABLET;ORAL | 019385-001 | Dec 30, 1988 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Valeant Pharm Intl | BENOQUIN | monobenzone | CREAM;TOPICAL | 008173-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Valeant Intl | RETIN-A | tretinoin | SWAB;TOPICAL | 016921-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Valeant
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Valeant Pharm Intl | PERMAX | pergolide mesylate | TABLET;ORAL | 019385-001 | Dec 30, 1988 | 4,797,405 | ⤷ Start Trial |
| Valeant Pharm Intl | PERMAX | pergolide mesylate | TABLET;ORAL | 019385-001 | Dec 30, 1988 | 4,166,182 | ⤷ Start Trial |
| Valeant Pharm Intl | LIBRELEASE | chlordiazepoxide | CAPSULE, EXTENDED RELEASE;ORAL | 017813-001 | Sep 12, 1983 | 4,316,897 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for VALEANT drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Tablets | 100 mg | ➤ Subscribe | 2007-01-08 |
| ➤ Subscribe | Extended-release Tablets | 300 mg | ➤ Subscribe | 2007-09-25 |
| ➤ Subscribe | Extended-release Tablets | 200 mg | ➤ Subscribe | 2007-03-28 |
| ➤ Subscribe | Tablets | 1.1 g | ➤ Subscribe | 2013-11-05 |
International Patents for Valeant Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 2668441 | ⤷ Start Trial |
| South Korea | 20140098863 | ⤷ Start Trial |
| China | 102670626 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Valeant Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1539166 | SPC/GB13/070 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: THE COMBINATION OF: (A) DEXTROMETHORPHAN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, E.G. DEXTROMETHORPHAN HYDROBROMIDE AND IN PARTICULAR DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; AND (B) QUINIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, E.G. Q; REGISTERED: UK EU/1/13/833 20130626 |
| 0566709 | SPC/GB04/012 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: TRAMADOL HYDROCHLORIDE, PARACETAMOL; REGISTERED: FR NL 25970 20020405; UK PL 00242/0384 20030925 |
| 1304992 | 2013C/060 | Belgium | ⤷ Start Trial | PRODUCT NAME: CLINDAMYCINE (ALS CLINDAMYCINE FOSFAAT) EN TRETINOINE; AUTHORISATION NUMBER AND DATE: BE437507 20130506 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
